Rare Disease Diagnostics Market

研究執行與發布：Coherent Market Insights　·　發布日期 2026-09-22　·　250 頁
由量子訊息有限公司（Quantum Information）在台灣代理銷售與提供授權諮詢。

2026 年市場規模: USD 2.86 Bn
2033 年預估規模: USD 7.13 Bn
年複合成長率 CAGR: 13.9%

以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。

完整報告名稱與涵蓋範圍

Rare Disease Diagnostics Market, By Test Type (Genetic Testing, Biochemical Testing, Molecular Diagnostics, Imaging Diagnostics, Others), By Technology (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Sanger Sequencing, Microarray, Mass Spectrometry, Immunoassays, Others), By Disease Type (Neurological Disorders, Metabolic and Endocrine Disorders, Hematological Disorders, Immunological Disorders, Cardiovascular Disorders, Genetic Cancers, Musculoskeletal Disorders, Others), By Sample Type (Blood, Saliva, Buccal Swab, Urine, Tissue, Cerebrospinal Fluid (CSF), Others), By End User (Diagnostic Laboratories, Hospitals and Clinics, Research and Academic Institutions, Pharmaceutical and Biotechnology Companies, Others), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa)

報告摘要

The global rare disease diagnostics market is estimated to be valued at USD 2.86 Bn in 2026 and is expected to reach USD 7.13 Bn by 2033, exhibiting a compound annual growth rate (CAGR) of 13.9% from 2026 to 2033. Rare diseases, also known as orphan diseases, affect a small percentage of the population, usually less than 200,000 people in the U.S. or fewer than 1 in 2,000 people in Europe. In total, more than 7,000 rare diseases affect more than 300 million people worldwide, most of which are of genetic origin. The market covers the technologies and methods used to identify, confirm and monitor these complicated and heterogeneous conditions The market includes genome sequencing, biomarker analysis, enzyme assays, imaging technologies, and next-generation sequencing platforms. Increasing disease awareness, advances in genomic technologies, rising investment by pharmaceutical and biotechnology companies, and supportive regulatory structures are contributing to market growth, while the complexity of rare diseases and extended diagnostic journeys continue to highlight the need for faster and more accurate diagnostic solutions Market Dynamics The global rare disease diagnostics market is driven by the increasing awareness about rare genetic conditions and the increasing demand for early and accurate diagnosis. Advances in next-generation sequencing (NGS), whole genome sequencing, biomarker analysis and AI-enabled diagnostics are playing a vital role in improving the detection of diseases at the molecular scale and reducing the diagnostic timelines. The government incentives and favorable regulatory landscape in the key markets are further supporting the investments and innovations in the area of rare disease diagnostics However, a number of constraints are present in the market, such as high costs of testing, limited availability of specialized diagnostic expertise, the lack of adequate healthcare infrastructure and the highly fragmented patient population especially in the developing economies. Meanwhile, the expansion of newborn screening programs, precision medicine initiatives, digital health platforms, and patient registries are creating opportunities to enable earlier diagnosis and wider access to specialized testing while the increasing investments in the development of rare disease diagnostic infrastructure in emerging markets are supporting the future market expansion. Key Features of the Study • This report provides in-depth analysis of the global rare disease diagnostics market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players • It profiles key players in the global rare disease diagnostics market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies • Key companies covered as a part of this study include Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd., Quest Diagnostics Incorporated, Laboratory Corporation of America Holdings, Illumina, Inc., Eurofins Scientific SE, QIAGEN N.V., Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., and CENTOGENE N.V. • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics • The global rare disease diagnostics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global rare disease diagnostics market Market Segmentation • Test Type Insights (Revenue, USD Bn, 2021 - 2033) o Genetic Testing o Biochemical Testing o Molecular Diagnostics o Imaging Diagnostics o Others • Technology Insights (Revenue, USD Bn, 2021 - 2033) o Next-Generation Sequencing (NGS) o Polymerase Chain Reaction (PCR) o Sanger Sequencing o Microarray o Mass Spectrometry o Immunoassays o Others • Disease Type Insights (Revenue, USD Bn, 2021 - 2033) o Neurological Disorders o Metabolic and Endocrine Disorders o Hematological Disorders o Immunological Disorders o Cardiovascular Disorders o Genetic Cancers o Musculoskeletal Disorders o Others • Sample Type Insights (Revenue, USD Bn, 2021 - 2033) o Blood o Saliva o Buccal Swab o Urine o Tissue o Cerebrospinal Fluid (CSF) o Others • End User Insights (Revenue, USD Bn, 2021 - 2033) o Diagnostic Laboratories o Hospitals and Clinics o Research and Academic Institutions o Pharmaceutical and Biotechnology Companies o Others • Regional Insights (Revenue, USD Bn, 2021 - 2033) o North America  U.S.  Canada o Latin America  Brazil  Argentina  Mexico  Rest of Latin America o Europe  Germany  U.K.  Spain  France  Italy  Russia  Rest of Europe o Asia Pacific  China  India  Japan  Australia  South Korea  ASEAN  Rest of Asia Pacific o Middle East  GCC Countries  Israel  Rest of Middle East o Africa  South Africa  North Africa  Central Africa • Key Players Insights o Thermo Fisher Scientific Inc. o F. Hoffmann-La Roche Ltd. o Quest Diagnostics Incorporated o Laboratory Corporation of America Holdings o Illumina, Inc. o Eurofins Scientific SE o QIAGEN N.V. o Agilent Technologies, Inc. o Bio-Rad Laboratories, Inc. o CENTOGENE N.V.

授權報價

Single User Price	$4,500 USD
Enterprise License	$10,000 USD

目錄 Table of Contents

Table of Contents 1. Research Objectives and Assumptions o Research Objectives o Assumptions o Abbreviations 2. Market Purview o Report Description  Market Definition and Scope o Executive Summary  Global Rare Disease Diagnostics Market, By Test Type  Global Rare Disease Diagnostics Market, By Technology  Global Rare Disease Diagnostics Market, By Disease Type  Global Rare Disease Diagnostics Market, By Sample Type  Global Rare Disease Diagnostics Market, By End User  Global Rare Disease Diagnostics Market, By Region 3. Market Dynamics, Regulations, and Trends Analysis o Market Dynamics o Impact Analysis o Key Highlights o Regulatory Scenario o Test Type Launches/Approvals o PEST Analysis o PORTER’s Analysis o Market Opportunities o Industry Trends 4. Global Rare Disease Diagnostics Market, By Test Type, 2021-2033, (USD Bn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022 - 2033  Segment Trends o Genetic Testing  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Biochemical Testing  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Molecular Diagnostics  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Imaging Diagnostics  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Others  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) 5. Global Rare Disease Diagnostics Market, By Technology, 2021-2033, (USD Bn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022 - 2033  Segment Trends o Next-Generation Sequencing (NGS)  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Polymerase Chain Reaction (PCR)  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Sanger Sequencing  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Microarray  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Mass Spectrometry  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Immunoassays  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Others  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) 6. Global Rare Disease Diagnostics Market, By Disease Type, 2021-2033, (USD Bn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022 - 2033  Segment Trends o Neurological Disorders  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Metabolic and Endocrine Disorders  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Hematological Disorders  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Immunological Disorders  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Cardiovascular Disorders  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Genetic Cancers  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Musculoskeletal Disorders  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Others  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) 7. Global Rare Disease Diagnostics Market, By Sample Type, 2021-2033, (USD Bn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022 - 2033  Segment Trends o Blood  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Saliva  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Buccal Swab  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Urine  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Tissue  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Cerebrospinal Fluid (CSF)  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Others  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) 8. Global Rare Disease Diagnostics Market, By End User, 2021-2033, (USD Bn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022 - 2033  Segment Trends o Diagnostic Laboratories  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Hospitals and Clinics  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Research and Academic Institutions  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Pharmaceutical and Biotechnology Companies  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Others  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) 9. Global Rare Disease Diagnostics Market, By Region, 2021 - 2033, Value (USD Bn) o Introduction  Market Share (%) Analysis, 2026, 2029 & 2033, Value (USD Bn)  Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)  Regional Trends o North America  Introduction  Market Size and Forecast, By Test Type, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Sample Type, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn) o U.S. o Canada o Latin America  Introduction  Market Size and Forecast, By Test Type, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Sample Type, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn) o Brazil o Argentina o Mexico o Rest of Latin America o Europe  Introduction  Market Size and Forecast, By Test Type, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Sample Type, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn) o Germany o U.K. o Spain o France o Italy o Russia o Rest of Europe o Asia Pacific  Introduction  Market Size and Forecast, By Test Type, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Sample Type, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn) o China o India o Japan o Australia o South Korea o ASEAN o Rest of Asia Pacific o Middle East  Introduction  Market Size and Forecast, By Test Type, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Sample Type, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn) o GCC Countries o Israel o Rest of Middle East o Africa  Introduction  Market Size and Forecast, By Test Type, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Sample Type, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn) o South Africa o North Africa o Central Africa 10. Competitive Landscape o Thermo Fisher Scientific Inc.  Company Highlights  Test Type Portfolio  Key Developments  Financial Performance  Strategies o F. Hoffmann-La Roche Ltd.  Company Highlights  Test Type Portfolio  Key Developments  Financial Performance  Strategies o Quest Diagnostics Incorporated  Company Highlights  Test Type Portfolio  Key Developments  Financial Performance  Strategies o Laboratory Corporation of America Holdings  Company Highlights  Test Type Portfolio  Key Developments  Financial Performance  Strategies o Illumina, Inc.  Company Highlights  Test Type Portfolio  Key Developments  Financial Performance  Strategies o Eurofins Scientific SE  Company Highlights  Test Type Portfolio  Key Developments  Financial Performance  Strategies o QIAGEN N.V.  Company Highlights  Test Type Portfolio  Key Developments  Financial Performance  Strategies o Agilent Technologies, Inc.  Company Highlights  Test Type Portfolio  Key Developments  Financial Performance  Strategies o Bio-Rad Laboratories, Inc.  Company Highlights  Test Type Portfolio  Key Developments  Financial Performance  Strategies o CENTOGENE N.V.  Company Highlights  Test Type Portfolio  Key Developments  Financial Performance  Strategies 11. Analyst Recommendations o Wheel of Fortune o Analyst View o Coherent Opportunity Map 12. References and Research Methodology o References o Research Methodology o About us *Browse 32 market data tables and 28 figures on ‘Rare Disease Diagnostics Market' - Global forecast to 2033

提及公司

Thermo Fisher Scientific Inc.F. Hoffmann-La Roche Ltd.Quest Diagnostics IncorporatedLaboratory Corporation of America HoldingsIllumina, Inc.Eurofins Scientific SEQIAGEN N.V.Agilent Technologies, Inc.Bio-Rad Laboratories, Inc.CENTOGENE N.V.

常見問題

這份報告可以先索取樣本嗎？

可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。

報告價格如何計算？

報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。

下單後多久交付？如何付款？

一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。

量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・聯絡我們